The need for low toxic anticancer compound with novel biological characteristics 3 . Various antioxidant effects have antiradical and antioxidative/prooxidative mechanism of been ascribed to flavonoids, viz., the scavenging of free action is in great demand. Consequently, there has been radicals, the chelation of transition metals and the growing interest in a number of phytochemicals, inhibition of free radicals producing enzymes 4 . In the polyphenolic compounds which have long been series tested, the scavenging ability nicely correlated with recognized to possess many potentially significant benefits, the number of free aromatic hydroxyl groups. Flavonoids including anticarcinogenic, antioxidant, antiviral and have been found to have a marked selectivity against antiproliferative activities 1 . Dietary factors contribute to malignant cell types in vitro [5] [6] [7] [8] . We reported previously about one-third of potentially preventable cancers, and that quercetin (Q) inhibits K-562 leukaemic cell the long-term preventive effects of plant-based diets on proliferation and induces apoptosis 9 . We initiated tumourigenesis, as well as therapeutic advantages, are antitumour investigation in animal models involving the well documented 2 .
growth of transplantable tumour to explore the feasibility In recent years, there has been a growing body of evidence that the major flavonoids (polyphenolics) can inhibit in vitro as well as in vivo tumour cell growth and induce apoptotic death of cells in different cell lines 3 . Flavonoids, a group of polyphenolic quinoids, are widely distributed in edible plants, edible fruits, leafy vegetables, roots, tubers, bulbs, herbs, spices, legumes, tea, coffee, red wine and beer. We consume these flavonoids through our everyday diet. These flavonoids possess a wide range of both potentially detrimental and protective *For correspondence E-mail: aingle@actrec.gov.in for further development of this dietary microchemical [11] [12] . In this primary study, we investigated the effect of quercetin on eliminating solid tumour growth and increased survival of tumour-bearing animals. We also studied combined antiproliferative effect of quercetin in vivo on growth of mammary tumour along with cyclophosphamide, a known cytotoxic drug. In addition, we made attempts to investigate the role of quercetin in protecting mice from radiation-induced injuries.
MATERIALS AND METHODS
Quercetin and dimethyl sulfoxide (DMSO) were purchased from SD Fine Chemicals, Mumbai. A stock www.ijpsonline.com solution of quercetin (200 mg/ml) in DMSO was prepared. Quercetin is freely soluble in DMSO.
Female C3H/J mice, Swiss mice and Wistar rats of either strain, procured from the animal faculty of Cancer Research Institute, were housed under the following conditions: Room temperature 22°C ±2, relative humidity 55% ±5, dark and light period of 12 h, free access to standard pelleted animal feed and water. Animals were randomly divided into experimental groups.
aged 6-8 w old (n = 10) for 9 consecutive days at a dose of 100 mg/kg. Six to eight weeks old male Swiss mice were injected intraperitoneally (i.p.) with 25, 50 and 100 mg/kg quercetin Bone marrow protection test: daily for 9 consecutive days (n = 6). DMSO stock Swiss mice were divided into four groups; each group solution (0.5 ml) of quercetin was taken in Tween 80 (1 consisted of five mice and was treated as follows. Control ml) and diluted with normal saline to make 10 ml animals were injected i.p. with 0.2 ml of the vehicle, injectable fine suspension and administered in a volume DMSO-Tween 80-saline (0.5:1:8.5) for 5 d. Quercetin (Q) of 0.1 ml per 10 g of body weight. Animals were alone was injected i.p. -100 mg/kg body weight of weighed every 24-48 h and observed every morning and quercetin for 5 d. Radiation (RT) alone requires exposure evening for mortality, if any. Results were recorded and to 800 rads of gamma radiation locally to the abdominal area expressed as maximum gain in weight compared to of mice on day 6. Quercetin with radiation (Q+RT) group controls, median day of death of animals and percentage animals were injected i.p. for 5 d with 100 mg/kg body mortality for each group. The maximum tolerated dose weight Q and exposed to 800 rads of gamma radiation after (MTD) was defined as a dose causing significant and 24 h of drug treatment (on day 6). reversible body weight loss (5-20%) but no morbidity 13 .
Whole blood was collected from the tail vein or by
After the radiation exposure, animals were sacrificed by cardiac puncture under light anaesthesia for the cervical dislocation, and bone marrow cells were collected determination of peripheral blood counts from three mice from the femur and tibias by flushing with Iscove's of each group after the completion of treatment (day 10). modified Dulbecco's Medium (IMDM). Red blood cells in marrow cells were haemolysed in 0.017 M Tris HCL, pH Collection and processing of blood samples:
7.5, buffer containing 0.8% ammonium chloride. Measurements of serum glutamate oxalo transferase Haemolysed bone marrow suspensions were rinsed twice (SGOT), serum glutamate pyruvate transferase (SGPT), with PBS, and viability was measured by trypan blue dye glucose, urea nitrogen, creatinine, haemoglobin and exclusion test on day 2 and day 4 during the post creatinine kinase were performed using the serum collected irradiation period 9 . from blood of Wistar rats treated for 4 d with quercetin.
. Control animals were treated with DMSO-Tween 80 saline (0.5:1:8.5). Since use of mice requires accumulation of serum for biochemical parameters, rats were preferred in this study to get sufficient quantity of serum.
Cytoreduction assay:
Mice of the control and quercetin-treated group were sacrificed at the end of the treatment period. Spleens were excised, blotted, weighed and fixed in 10% formalin for 24 h, and ovaries (from the same animals' uteri) were dissected, blotted and weighed.
Spleen colony assay:
Quercetin was administered i.p. daily in Swiss male mice Animal tumour models: Sarcoma-180 ascitic tumour (2 × 10 6 cells/animals) was inoculated i.p. into 4-6 w old Swiss mice of either sex. Quercetin at dose levels of 25, 50, 100 mg/kg was administered for nine days, 24 h after tumour inoculation, and deaths were recorded everyday, if any. www.ijpsonline.com
The control group was treated by daily i.p. injection of 0.2 ml of the drug vehicle. Tumour progression was monitored for 3 w by skin calliper measurements. The ratio of mean tumour volume of treated group to that of control group (T/C) was calculated at 21 days. Maximum tumour regression was defined as the smallest relative tumour volume achieved throughout the treatment course. Tumour growth delay was the time required for the tumour to double in volume. Tumour volume (V) was calculated according to the equation V = a×b 2 /2, where a = longest diameter, b = longest diameter at right angles comparable in both the experimental groups, the overall data indicates quercetin's lack of cytoreduction activity To increase efficacy of cyclophosphamide (CTX) against (Table 3) . Since Q was administered in the suspension the established mammary tumour (Table 5 ) in C3H/J mice, form, there is bound to be slight increase in the weights each set of six mice were stratified into four groups of some of the organs. Spleen colony assay points out (Control, Q, CTX, Q+CTX). Quercetin (100 mg/kg) alone that administration of quercetin repeatedly at its MTD has or along with CTX (50 mg/kg) was administered by i.p.
no adverse effects on the bone marrow cells of treated route keeping 3 h gap between the two injections on mice. The number of colonies in IR, control and Q days 1, 5, 9. Control mice were treated with vehicle by treated groups was 1, 11.8 and 12.8 respectively. three i.p. injections, 4 d apart from each other. Tumour volume was measured twice-weekly using skin callipers as It is well recognized that a large dose of irradiation can described above.
lead to acute or progressive biological effects and thus can be used in clinics to treat patients with malignancies.
RESULTS AND DISCUSSION
When used against tumours, radiation also exerts destructive effects on haematopoietic organs such as the Hertog and Hollman have reviewed the potential health spleen, thymus and bone marrow and this damage usually effects of quercetin
10
. The compound is a bioflavonoid, appears with the pronounced syndromes of these systems, which exists in a free or configurated form in many fruits and vegetables. Despite important advances, the assess the efficacy of quercetin in suppressing mouse mammary tumour and increasing the lifespan of S-180 tumour bearing animals after assessing its biological properties.
Toxic side effects of quercetin which have been reported so far include damage to gastrointestinal tract and kidney 10 . To avoid undesirable side effects, we first determined its MTD. Solubility problem arose because of its hydrophobic nature 9 . A fine suspension was prepared from its stock solution, and the MTD was found to be 100 mg/kg in mice dose; there was no apparent decrease in body weight and mortality (Table 1 ). This dose was used for all further studies. The pattern of changes in blood constituents after in vivo treatment with Q (100 mg/kg) for 9 consecutive days. Blood samples were withdrawn from tail vein following the completion of treatment www.ijpsonline.com including leucopoenia, haemorrhage, infection and anaemia. In radiation therapy, how to eliminate the tumour growth and in the meantime possibly enhance the recovery of haematopoietic organs from injuries seemed important. Using flavonoids, we are trying to achieve a significant reduction of tumour growth in experimental tumour systems against radiation-induced damage. In the earlier experiments, we have found that quercetin created hypoxic conditions in tumour tissue (data not shown). Cells in hypoxic state are known to be resistant to chemotherapeutic and radiation treatment 11 . Whether to individual group of quercetin and cyclophosphamide. By 2 w after quercetin treatment, retardation of growth became apparent; and by 3 w, difference in mean tumour volume of the individual groups and combined group reached statistically significant levels. By 4 w, when the tumour had enlarged to the extent that necrosis and rupture had occurred, all measurements of size and body weights were discontinued since data obtained beyond this point would not have been meaningful.
The effects of 25, 50 and 100 mg/kg of quercetin on this property can make it a radioprotective agent has survival of S-180 tumour bearing mice given on days 1-9, remained to be shown. Working on similar lines, we were i.p., 24 h after S-180 tumour cell transplantation are shown able to show that quercetin protects mouse bone marrow in Table 5 . Antitumour effect at 100 mg/kg was significantly cells from radiation toxic effect. Bone marrow cell counts higher than with treatments at lower doses. Fifty percent of of different groups differ according to treatment given. the animals survived for more than 2 mo. The effects of The bone marrow cell counts in radiation-treated group quercetin were more pronounced when given after 24 h of were the lowest, but if the same group received cell inoculation than after day 5 of the experiment -that is, quercetin prior to radiation, there was protection to the late treatment (Table 6 ). It appears that the presence of the level of 50% (Table 4) . Serum obtained from quercetin-C2-C3 double bond and/or attachment of ring B to the treated Wistar rats was used for enzymatic studies.
chromone structure besides hydroxylation at the 3 position Hypoxic conditions created by quercetin resulted in high are/is responsible for the antitumour effects shown by lactate levels. However, there was no corresponding quercetin flavonol
5
. Based on the above results, quercetin increase in the levels of acid and alkaline phosphatase was co-administered with various cytotoxic drugs. The (data not shown).
flavonoids enhanced the antitumour activity of cisplatin (data not shown). In 1971 quercetin was discovered to moderately inhibit the growth of i.p. implanted P388 leukaemia, increasing
We determined the MTD of quercetin, as well as the lifespan of the tumour-bearing mice by 27-32% 15 . At toxicological profile, using a suitable vehicle for its safe that time the level of P388 activity demonstrated by quercetin was not considered sufficient to warrant further human tumours, it is now being re-examined by us 5, 9, 10 . In Comparative survival patterns of tumour-bearing mice treated with Q with different doses. Control group was treated with vehicle only. Quercetin was i.p. administered daily, day 1 to day 9, to tumour-bearing mice. Statistical significance at *P < 0.05; **P < 0.01 by the student's 't' test www.ijpsonline.com administration, which will be useful for carrying out non-nutrient appears to be useful as a supplementary 12. Indap, M.A., Bhosle, S.C., Vavia, P.R. and. Tayade, P.T., Indian product in combination therapy, which may have Drugs, 1998, 35, 545. therapeutic significance. Earlier we have proved that 13. Indap, M.A., Bhosle, S.C., Tayade, P. T. and Vavia, P.R., Indian J.
Pharm. Sci., 2002, 64, 4, 349. quercetin shows vasoactive properties. This finding, 
